Lexicon's sotagliflozin reduces clot formation in small healthy-volunteer study
LXRX•Lexicon Pharmaceuticals said a randomized crossover study in 15 healthy adults found sotagliflozin significantly reduced clot formation; reductions with empagliflozin were not statistically significant.
1. Study findings
Lexicon Pharmaceuticals presented two sotagliflozin studies at the 2026 American Heart Association Scientific Sessions. In a randomized crossover trial involving 15 healthy adults, sotagliflozin significantly reduced clot formation, while reductions with empagliflozin were not statistically significant.
2. Heart tissue research
A separate study using human heart tissue found sotagliflozin directly reduced heart muscle workload and was more potent than empagliflozin under conditions mimicking hypertrophic cardiomyopathy.
3. Phase 3 trial
Lexicon's ongoing Phase 3 SONATA-HCM trial targets symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy, with topline results expected in the first quarter of 2027.
